BIOMAT Database Logo BIOMAT Database Logo

Synthesis and evaluation of novel HCV replication inhibitors. 2017

David C McGowan, and Mourad D Khamlichi, and Alex De Groot, and Frederik Pauwels, and Frédéric Delouvroy, and Kristof Van Emelen, and Kenneth Simmen, and Pierre Raboisson
Janssen Infectious Diseases BVBA, Turnhoutseweg 30, 2340, Beerse, Belgium. dmcgowan@its.jnj.com.

Direct acting antiviral agents to cure hepatitis C virus (HCV) infection has emerged as the gold standard therapy. Along with protease inhibitors, nucleoside polymerase inhibitors and non-nucleoside polymerase inhibitors, the inhibition of NS5a has proved to be an effective way to treat HCV patients. Here we report on novel HCV NS5a inhibitors which were synthesized and evaluated in the HCV replicon assay. A series of inhibitors were formed by a cycloaddition reaction in parallel to establish new leads and explore the effects of unsymmetrical cap substitution. This led to the identification of several triazoles with picomolar potency in vitro against hepatitis C virus.

UI MeSH Term Description Entries
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D016174 Hepacivirus A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species. Hepatitis C virus,Hepatitis C-Like Viruses,Hepaciviruses,Hepatitis C Like Viruses,Hepatitis C viruses,Hepatitis C-Like Virus
D017361 Viral Nonstructural Proteins Proteins encoded by a VIRAL GENOME that are not structural components of VIRUS PARTICLES. Some of these proteins may play roles within the infected cell during VIRUS REPLICATION or act in regulation of virus replication or VIRUS ASSEMBLY. Nonstructural Proteins, Viral,NS Proteins, Viral,Viral NS Proteins,Viral Non-Structural Proteins,Viral Nonstructural Protein,Viral Nonstructural Proteins NS1,Viral Nonstructural Proteins NS2,Nonstructural Protein, Viral,Viral Non Structural Proteins
D060326 Chemistry Techniques, Synthetic Methods used for the chemical synthesis of compounds. Included under this heading are laboratory methods used to synthesize a variety of chemicals and drugs. Inorganic Synthesis,Inorganic Synthesis Methods,Inorganic Synthesis Techniques,Methods of Inorganic Synthesis,Methods of Organic Synthesis,Methods of Peptide Synthesis,Organic Synthesis,Organic Synthesis Methods,Organic Synthesis Techniques,Peptide Synthesis Methods,Peptide Synthesis Techniques,Peptide Synthesis, Synthetic,Synthetic Chemistry Techniques,Synthetic Peptide Synthesis,Chemistry Technique, Synthetic,Inorganic Syntheses,Inorganic Synthesis Method,Inorganic Synthesis Technique,Method, Inorganic Synthesis,Method, Organic Synthesis,Method, Peptide Synthesis,Methods, Inorganic Synthesis,Methods, Organic Synthesis,Methods, Peptide Synthesis,Organic Syntheses,Organic Synthesis Technique,Peptide Syntheses, Synthetic,Peptide Synthesis Method,Peptide Synthesis Technique,Syntheses, Inorganic,Syntheses, Organic,Syntheses, Synthetic Peptide,Synthesis Method, Inorganic,Synthesis Method, Peptide,Synthesis Methods, Inorganic,Synthesis Methods, Peptide,Synthesis Technique, Inorganic,Synthesis Technique, Organic,Synthesis Technique, Peptide,Synthesis Techniques, Inorganic,Synthesis Techniques, Organic,Synthesis Techniques, Peptide,Synthesis, Inorganic,Synthesis, Organic,Synthesis, Synthetic Peptide,Synthetic Chemistry Technique,Synthetic Peptide Syntheses,Technique, Inorganic Synthesis,Technique, Organic Synthesis,Technique, Peptide Synthesis,Technique, Synthetic Chemistry,Techniques, Inorganic Synthesis,Techniques, Organic Synthesis,Techniques, Peptide Synthesis,Techniques, Synthetic Chemistry

Related Publications

David C McGowan, and Mourad D Khamlichi, and Alex De Groot, and Frederik Pauwels, and Frédéric Delouvroy, and Kristof Van Emelen, and Kenneth Simmen, and Pierre Raboisson
Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication.
November 2016, European journal of medicinal chemistry,
David C McGowan, and Mourad D Khamlichi, and Alex De Groot, and Frederik Pauwels, and Frédéric Delouvroy, and Kristof Van Emelen, and Kenneth Simmen, and Pierre Raboisson
Synthesis and evaluation of novel potent HCV NS5A inhibitors.
July 2012, Bioorganic & medicinal chemistry letters,
David C McGowan, and Mourad D Khamlichi, and Alex De Groot, and Frederik Pauwels, and Frédéric Delouvroy, and Kristof Van Emelen, and Kenneth Simmen, and Pierre Raboisson
Novel substituted pyrimidines as HCV replication (replicase) inhibitors.
January 2012, Bioorganic & medicinal chemistry letters,
David C McGowan, and Mourad D Khamlichi, and Alex De Groot, and Frederik Pauwels, and Frédéric Delouvroy, and Kristof Van Emelen, and Kenneth Simmen, and Pierre Raboisson
Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors.
September 2012, Bioorganic & medicinal chemistry letters,
David C McGowan, and Mourad D Khamlichi, and Alex De Groot, and Frederik Pauwels, and Frédéric Delouvroy, and Kristof Van Emelen, and Kenneth Simmen, and Pierre Raboisson
Synthesis and Evaluation of 2,6-Modified Purine 2'-C-Methyl Ribonucleosides as Inhibitors of HCV Replication.
January 2016, ACS medicinal chemistry letters,
David C McGowan, and Mourad D Khamlichi, and Alex De Groot, and Frederik Pauwels, and Frédéric Delouvroy, and Kristof Van Emelen, and Kenneth Simmen, and Pierre Raboisson
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
April 2013, Bioorganic & medicinal chemistry letters,
David C McGowan, and Mourad D Khamlichi, and Alex De Groot, and Frederik Pauwels, and Frédéric Delouvroy, and Kristof Van Emelen, and Kenneth Simmen, and Pierre Raboisson
Synthesis and biological evaluation of triazolothienopyrimidine derivatives as novel HIV-1 replication inhibitors.
January 2013, Bioorganic & medicinal chemistry letters,
David C McGowan, and Mourad D Khamlichi, and Alex De Groot, and Frederik Pauwels, and Frédéric Delouvroy, and Kristof Van Emelen, and Kenneth Simmen, and Pierre Raboisson
HCV NS5A replication complex inhibitors.
October 2016, Current opinion in pharmacology,
David C McGowan, and Mourad D Khamlichi, and Alex De Groot, and Frederik Pauwels, and Frédéric Delouvroy, and Kristof Van Emelen, and Kenneth Simmen, and Pierre Raboisson
Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease.
June 2010, Bioorganic & medicinal chemistry letters,
David C McGowan, and Mourad D Khamlichi, and Alex De Groot, and Frederik Pauwels, and Frédéric Delouvroy, and Kristof Van Emelen, and Kenneth Simmen, and Pierre Raboisson
Synthesis and biological evaluation of novel pentacyclic triterpene α-cyclodextrin conjugates as HCV entry inhibitors.
November 2016, European journal of medicinal chemistry,
Copied contents to your clipboard!